Advice

following a resubmission:

fampridine (Fampyra®) is not recommended for use within NHSScotland.

Indication under review: For the improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS [expanded disability status scale] 4-7).

In double-blind phase III studies fampridine, compared with placebo, improved walking ability in adults with multiple sclerosis and walking impairment.

The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.

Medicine details

Medicine name:
fampridine (Fampyra)
SMC ID:
SMC2107
Indication:
is indicated for the improvement of walking in adult patients with multiple sclerosis (MS) with walking disability (expanded disability status score [EDSS] 4–7)
Pharmaceutical company
Biogen Idec Ltd
BNF chapter
Central nervous system
Submission type
Resubmission
Status
Not recommended
Date advice published:
12 November 2018